› Forums › General Melanoma Community › Graves Disease / Gluacoma and IPI?
- This topic has 3 replies, 1 voice, and was last updated 10 years, 7 months ago by MaryD.
- Post
-
- September 29, 2013 at 2:17 pm
I experienced side effects of the eye while on Ipi trial (10MG/KG compassionate use) way back in 2009, and just this year was diagnosed with thryoid issue, Graves Disease and very early Glaucoma. Wondering if anyone who had the same strength dose of Ipi while on trial have experienced eye issues since stopping?
– Just Curious
-Rocco
- Replies
-
-
- September 29, 2013 at 8:09 pm
How coincidential you should mention this – I was on that dose for an Ipi trial for resected melanoma in 2008.
I was just diagnosed two weeks ago with Glaucoma but I highly suspect it may relate to a med, Topamax, I was taking for fibromyalgia and have stopped it.
However, I did send an email to Dr. Weber at Moffit (where I did the trial) and asked him if there could be any link to immunotherapy. He didn't feel that it was likely . . .but since all of these drugs are so new, guess we never know what might develop down the road.
Mary
-
- September 29, 2013 at 8:09 pm
How coincidential you should mention this – I was on that dose for an Ipi trial for resected melanoma in 2008.
I was just diagnosed two weeks ago with Glaucoma but I highly suspect it may relate to a med, Topamax, I was taking for fibromyalgia and have stopped it.
However, I did send an email to Dr. Weber at Moffit (where I did the trial) and asked him if there could be any link to immunotherapy. He didn't feel that it was likely . . .but since all of these drugs are so new, guess we never know what might develop down the road.
Mary
-
- September 29, 2013 at 8:09 pm
How coincidential you should mention this – I was on that dose for an Ipi trial for resected melanoma in 2008.
I was just diagnosed two weeks ago with Glaucoma but I highly suspect it may relate to a med, Topamax, I was taking for fibromyalgia and have stopped it.
However, I did send an email to Dr. Weber at Moffit (where I did the trial) and asked him if there could be any link to immunotherapy. He didn't feel that it was likely . . .but since all of these drugs are so new, guess we never know what might develop down the road.
Mary
-
- You must be logged in to reply to this topic.